海正药业
(600267)
| 流通市值：134.91亿 | | | 总市值：134.91亿 |
| 流通股本：11.80亿 | | | 总股本：11.80亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,475,493,027.22 | 2,390,467,858.12 | 10,549,640,956.88 | 7,922,794,186.82 |
| 营业收入 | 4,475,493,027.22 | 2,390,467,858.12 | 10,549,640,956.88 | 7,922,794,186.82 |
| 二、营业总成本 | 3,759,499,912.51 | 2,063,639,937.5 | 9,450,690,106.08 | 7,073,625,021.67 |
| 营业成本 | 1,988,189,757.58 | 1,174,489,303.32 | 5,819,865,024.29 | 4,358,649,302.4 |
| 税金及附加 | 56,314,197.24 | 33,028,244.9 | 117,265,693.11 | 83,988,165.73 |
| 销售费用 | 1,050,639,456.35 | 521,646,476.91 | 2,078,460,063.73 | 1,609,805,985.09 |
| 管理费用 | 364,996,622.14 | 184,807,282.73 | 872,523,571.04 | 587,921,517.94 |
| 研发费用 | 268,021,413.97 | 134,437,997.58 | 478,539,580.32 | 372,154,095.37 |
| 财务费用 | 31,338,465.23 | 15,230,632.06 | 84,036,173.59 | 61,105,955.14 |
| 其中:利息费用 | 28,684,991.8 | 16,722,345.83 | 100,076,115.64 | 78,464,830.99 |
| 其中:利息收入 | 5,919,461.83 | 4,114,299.69 | 20,854,594.46 | 17,064,722.46 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -1,161,748.71 | -378,922.12 | -34,782,686.47 | -36,370,692.67 |
| 加:投资收益 | 175,824,764.23 | 175,229,670.88 | -36,697,762.95 | -34,534,648.03 |
| 资产处置收益 | 849,833.5 | 1,046,511.6 | 5,234,365.98 | 2,340,902.89 |
| 资产减值损失(新) | -79,751,159.13 | -48,010,158.66 | -213,171,765.88 | -162,306,635.28 |
| 信用减值损失(新) | -15,554,768.76 | 7,881,191.13 | -50,563,585.41 | -44,600,711.67 |
| 其他收益 | 31,643,313.9 | 20,933,854.23 | 98,066,656.91 | 69,026,284.75 |
| 四、营业利润 | 827,843,349.74 | 483,530,067.68 | 867,036,072.98 | 642,723,665.14 |
| 加:营业外收入 | 4,222,681.64 | 475,293.27 | 8,337,490.04 | 7,572,600.25 |
| 减:营业外支出 | 8,491,000.24 | 1,545,328.07 | 59,997,450 | 30,561,126.79 |
| 五、利润总额 | 823,575,031.14 | 482,460,032.88 | 815,376,113.02 | 619,735,138.6 |
| 减:所得税费用 | 181,861,404.86 | 123,912,957.9 | 267,890,410.59 | 151,677,328.5 |
| 六、净利润 | 641,713,626.28 | 358,547,074.98 | 547,485,702.43 | 468,057,810.1 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 641,713,626.28 | 358,547,074.98 | 547,485,702.43 | 468,057,810.1 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 636,475,377.31 | 355,690,873.08 | 540,707,781.22 | 460,929,192.8 |
| 少数股东损益 | 5,238,248.97 | 2,856,201.9 | 6,777,921.21 | 7,128,617.3 |
| 扣除非经常损益后的净利润 | 513,270,359.72 | 235,775,846.48 | 585,676,238.11 | 490,513,193.75 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.55 | 0.31 | 0.46 | 0.4 |
| (二)稀释每股收益 | 0.55 | 0.31 | 0.46 | 0.4 |
| 八、其他综合收益 | -3,147,341.15 | -1,575,109.08 | -2,385,203.76 | -1,325,403.18 |
| 归属于母公司股东的其他综合收益 | -3,147,341.15 | -1,575,109.08 | -2,385,203.76 | -1,325,403.18 |
| 九、综合收益总额 | 638,566,285.13 | 356,971,965.9 | 545,100,498.67 | 466,732,406.92 |
| 归属于母公司股东的综合收益总额 | 633,328,036.16 | 354,115,764 | 538,322,577.46 | 459,603,789.62 |
| 归属于少数股东的综合收益总额 | 5,238,248.97 | 2,856,201.9 | 6,777,921.21 | 7,128,617.3 |
| 公告日期 | 2026-08-26 | 2026-04-28 | 2026-04-08 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |